Declaration of any potential conflicts of interests: Dr. Kendler—Consultant, Speaker's Bureau, and/or research grants: Merck, Amgen, Eli Lilly, Novartis, J&J, Roche, GSK, Pfizer.
The generalized bone phenotype in children with neurofibromatosis 1: A sibling matched case–control study
Article first published online: 24 MAY 2013
Copyright © 2013 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part A
Volume 161, Issue 7, pages 1654–1661, July 2013
How to Cite
2013. The generalized bone phenotype in children with neurofibromatosis 1: A sibling matched case–control study. Am J Med Genet Part A 161A:1654–1661., , , , , , , , , , .
- Issue published online: 19 JUN 2013
- Article first published online: 24 MAY 2013
- Manuscript Accepted: 28 MAR 2013
- Manuscript Received: 29 JUL 2012
- British Columbia Children's Hospital Telethon Grant
- British Columbia Neurofibromatosis Foundation (BCNF)
This article has been cited by:
- 1Is it time to change the neurofibromatosis 1 diagnostic criteria?, European Journal of Internal Medicine, 2014, 25, 6, 506, , , , , ,
- 2Pelvico-calyceal system rupture due to staghorn calculus with urinoma formation in a boy with neurofibromatosis type 1 and quadriplegia, Pediatria Polska, 2014, 89, 4, 302, , , , , , , , ,
- 3Quantitative Computer Tomography in Children and Adolescents: The 2013 ISCD Pediatric Official Positions, Journal of Clinical Densitometry, 2014, 17, 2, 258, , , ,